JP2016506388A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016506388A5 JP2016506388A5 JP2015545868A JP2015545868A JP2016506388A5 JP 2016506388 A5 JP2016506388 A5 JP 2016506388A5 JP 2015545868 A JP2015545868 A JP 2015545868A JP 2015545868 A JP2015545868 A JP 2015545868A JP 2016506388 A5 JP2016506388 A5 JP 2016506388A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- nos
- sequence consisting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 78
- -1 lenalidomide compound Chemical class 0.000 claims 29
- 229960004942 lenalidomide Drugs 0.000 claims 24
- 229960003957 dexamethasone Drugs 0.000 claims 18
- 239000003146 anticoagulant agent Substances 0.000 claims 12
- 229940127219 anticoagulant drug Drugs 0.000 claims 12
- 208000034578 Multiple myelomas Diseases 0.000 claims 10
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 10
- 239000002955 immunomodulating agent Substances 0.000 claims 10
- 229940121354 immunomodulator Drugs 0.000 claims 10
- 230000002584 immunomodulator Effects 0.000 claims 10
- 238000002560 therapeutic procedure Methods 0.000 claims 10
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 9
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 5
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 5
- 229960003433 thalidomide Drugs 0.000 claims 5
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 4
- 230000004540 complement-dependent cytotoxicity Effects 0.000 claims 4
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 2
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 2
- 230000006907 apoptotic process Effects 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 239000003055 low molecular weight heparin Substances 0.000 claims 2
- 229940127215 low-molecular weight heparin Drugs 0.000 claims 2
- 230000002195 synergetic effect Effects 0.000 claims 2
- 229960005080 warfarin Drugs 0.000 claims 2
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 claims 2
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261734524P | 2012-12-07 | 2012-12-07 | |
| US61/734,524 | 2012-12-07 | ||
| US201361769247P | 2013-02-26 | 2013-02-26 | |
| US61/769,247 | 2013-02-26 | ||
| US201361808372P | 2013-04-04 | 2013-04-04 | |
| US61/808,372 | 2013-04-04 | ||
| PCT/US2013/073540 WO2014089416A1 (en) | 2012-12-07 | 2013-12-06 | Compositions comprising anti-cd38 antibodies and lenalidomide |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019003132A Division JP2019070020A (ja) | 2012-12-07 | 2019-01-11 | 抗ｃｄ３８抗体及びレナリドマイドを含む組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016506388A JP2016506388A (ja) | 2016-03-03 |
| JP2016506388A5 true JP2016506388A5 (OSRAM) | 2017-01-19 |
| JP6499971B2 JP6499971B2 (ja) | 2019-04-10 |
Family
ID=50884019
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015545868A Active JP6499971B2 (ja) | 2012-12-07 | 2013-12-06 | 抗ｃｄ３８抗体及びレナリドマイドを含む組成物 |
| JP2019003132A Pending JP2019070020A (ja) | 2012-12-07 | 2019-01-11 | 抗ｃｄ３８抗体及びレナリドマイドを含む組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019003132A Pending JP2019070020A (ja) | 2012-12-07 | 2019-01-11 | 抗ｃｄ３８抗体及びレナリドマイドを含む組成物 |
Country Status (31)
| Country | Link |
|---|---|
| EP (2) | EP3597191A1 (OSRAM) |
| JP (2) | JP6499971B2 (OSRAM) |
| KR (2) | KR102193045B1 (OSRAM) |
| CN (1) | CN105263520B (OSRAM) |
| AR (1) | AR093844A1 (OSRAM) |
| AU (2) | AU2013355064B2 (OSRAM) |
| BR (1) | BR112015012987A2 (OSRAM) |
| CA (1) | CA2893946A1 (OSRAM) |
| CL (2) | CL2015001558A1 (OSRAM) |
| CY (2) | CY1122478T1 (OSRAM) |
| DK (1) | DK2928495T3 (OSRAM) |
| ES (1) | ES2731548T3 (OSRAM) |
| HR (1) | HRP20191034T1 (OSRAM) |
| HU (3) | HUE044142T2 (OSRAM) |
| IL (2) | IL239234B (OSRAM) |
| LT (2) | LT2928495T (OSRAM) |
| LU (1) | LUC00187I2 (OSRAM) |
| MX (2) | MX366296B (OSRAM) |
| MY (1) | MY191601A (OSRAM) |
| NL (1) | NL301079I2 (OSRAM) |
| NZ (1) | NZ709215A (OSRAM) |
| PH (1) | PH12015501263A1 (OSRAM) |
| PL (1) | PL2928495T3 (OSRAM) |
| PT (1) | PT2928495T (OSRAM) |
| RS (1) | RS58829B1 (OSRAM) |
| RU (1) | RU2698911C2 (OSRAM) |
| SG (3) | SG10201704536PA (OSRAM) |
| SI (1) | SI2928495T1 (OSRAM) |
| TW (2) | TWI670062B (OSRAM) |
| UA (1) | UA118255C2 (OSRAM) |
| WO (1) | WO2014089416A1 (OSRAM) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA112170C2 (uk) | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| US10342869B2 (en) | 2012-12-07 | 2019-07-09 | The Regents Of The University Of California | Compositions comprising anti-CD38 antibodies and lenalidomide |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| WO2015195555A1 (en) * | 2014-06-16 | 2015-12-23 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Blocking cd38 using anti-cd38 antibody conjugated to protein g to protect nk cells |
| US10617757B2 (en) | 2014-08-08 | 2020-04-14 | The Regents Of The University Of California | Methods for treating multiple myeloma |
| WO2016089960A1 (en) | 2014-12-04 | 2016-06-09 | Janssen Biotech, Inc. | Anti-cd38 antibodies for treatment of acute myeloid leukemia |
| MA42136A (fr) | 2015-05-20 | 2018-03-28 | Janssen Biotech Inc | Anticorps anti-cd38 pour le traitement de l'amyloïdose à chaînes légères et d'autres tumeurs malignes hématologiques positives à cd38 |
| US10668149B2 (en) | 2015-06-22 | 2020-06-02 | Janssen Biotech, Inc. | Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| PH12018500950B1 (en) | 2015-11-03 | 2023-09-20 | Janssen Biotech Inc | Subcutaneous formulations of anti-cd38 antibodies and their uses |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| JP7316930B2 (ja) | 2016-07-15 | 2023-07-28 | 武田薬品工業株式会社 | 形質芽細胞及び形質細胞枯渇療法に対する応答を評価するための方法及び材料 |
| US11618787B2 (en) | 2017-10-31 | 2023-04-04 | Janssen Biotech, Inc. | Methods of treating high risk multiple myeloma |
| CA3088199A1 (en) | 2018-01-12 | 2019-07-18 | Takeda Pharmaceutical Company Limited | Subcutaneous dosing of anti-cd38 antibodies |
| WO2019199133A1 (ko) * | 2018-04-13 | 2019-10-17 | 주식회사 삼양바이오팜 | 레날리도마이드의 경구용 코팅 정제 조성물 |
| WO2019199135A1 (ko) * | 2018-04-13 | 2019-10-17 | 주식회사 삼양바이오팜 | 레날리도마이드를 포함하는 경구용 고형제제의 제조방법 |
| WO2019199134A1 (ko) * | 2018-04-13 | 2019-10-17 | 주식회사 삼양바이오팜 | 레날리도마이드를 포함하는 약제학적 조성물 |
| KR102286500B1 (ko) * | 2018-04-13 | 2021-08-05 | 주식회사 삼양홀딩스 | 레날리도마이드를 포함하는 경구용 고형제제의 제조방법 |
| KR102286497B1 (ko) * | 2018-04-13 | 2021-08-05 | 주식회사 삼양홀딩스 | 다양한 용량의 레날리도마이드의 경구용 정제 조성물 |
| CA3100118A1 (en) | 2018-05-16 | 2019-11-21 | Janssen Biotech, Inc. | Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy |
| KR20210069642A (ko) * | 2018-10-01 | 2021-06-11 | 셀진 코포레이션 | 암 치료를 위한 병용 요법 |
| SG11202107319PA (en) * | 2019-03-15 | 2021-08-30 | Morphosys Ag | Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease |
| JP7705353B2 (ja) * | 2019-06-10 | 2025-07-09 | 武田薬品工業株式会社 | Ｃｄ３８抗体を使用する併用療法 |
| US11655302B2 (en) | 2019-06-10 | 2023-05-23 | Sanofi | Anti-CD38 antibodies and formulations |
| PH12022551008A1 (en) * | 2019-10-31 | 2023-03-20 | Morphosys Ag | Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma |
| US20210188996A1 (en) | 2019-12-05 | 2021-06-24 | Sanofi-Aventis U.S. Llc | Formulations of anti-cd38 antibodies for subcutaneous administration |
| US20250277051A1 (en) * | 2021-08-02 | 2025-09-04 | Hangzhou Unogen Biotech, Ltd | Anti-cd38 antibodies, anti-cd3 antibodies, and bispecific antibodies, and uses thereof |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| DE69637481T2 (de) | 1995-04-27 | 2009-04-09 | Amgen Fremont Inc. | Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| ES2301183T3 (es) | 1996-12-03 | 2008-06-16 | Amgen Fremont Inc. | Anticuerpo completamente humano que se une al receptor del egfr. |
| CN100387621C (zh) | 1997-04-14 | 2008-05-14 | 麦可麦脱股份公司 | 抗人抗原受体的新的生产方法及其用途 |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US20080153976A1 (en) * | 2004-12-21 | 2008-06-26 | Nippon Kayaku Kabushiki Kaisha | Epoxy Resin, Epoxy Resin Composition, And Cured Material Thereof |
| EA037929B1 (ru) * | 2005-03-23 | 2021-06-08 | Генмаб А/С | Антитела к cd38 человека и их применение |
| ME03503B (me) * | 2006-09-26 | 2020-04-20 | Genmab As | Anti-cd38 plus kortkosteroidni plus ne-kortikosteroidni hemoterapeutik za tretiranje tumora |
| EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| EP2191843A1 (en) * | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide |
| EP2191840A1 (en) * | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan |
| PL2621531T3 (pl) * | 2010-09-27 | 2017-07-31 | Morphosys Ag | Przeciwciało anty-CD38 i lenalidomid lub bortezomib do leczenia szpiczaka mnogiego i NHL |
| JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
-
2013
- 2013-06-12 UA UAA201506686A patent/UA118255C2/uk unknown
- 2013-12-06 SG SG10201704536PA patent/SG10201704536PA/en unknown
- 2013-12-06 ES ES13861470T patent/ES2731548T3/es active Active
- 2013-12-06 WO PCT/US2013/073540 patent/WO2014089416A1/en not_active Ceased
- 2013-12-06 JP JP2015545868A patent/JP6499971B2/ja active Active
- 2013-12-06 EP EP19164801.3A patent/EP3597191A1/en not_active Withdrawn
- 2013-12-06 HR HRP20191034TT patent/HRP20191034T1/hr unknown
- 2013-12-06 RU RU2015127089A patent/RU2698911C2/ru active
- 2013-12-06 HU HUE13861470A patent/HUE044142T2/hu unknown
- 2013-12-06 MX MX2015007189A patent/MX366296B/es active IP Right Grant
- 2013-12-06 PL PL13861470T patent/PL2928495T3/pl unknown
- 2013-12-06 MY MYPI2015701779A patent/MY191601A/en unknown
- 2013-12-06 PT PT13861470T patent/PT2928495T/pt unknown
- 2013-12-06 DK DK13861470.6T patent/DK2928495T3/da active
- 2013-12-06 RS RS20190711A patent/RS58829B1/sr unknown
- 2013-12-06 SG SG11201504315WA patent/SG11201504315WA/en unknown
- 2013-12-06 BR BR112015012987A patent/BR112015012987A2/pt not_active Application Discontinuation
- 2013-12-06 AU AU2013355064A patent/AU2013355064B2/en active Active
- 2013-12-06 EP EP13861470.6A patent/EP2928495B1/en active Active
- 2013-12-06 KR KR1020157017942A patent/KR102193045B1/ko active Active
- 2013-12-06 KR KR1020207035944A patent/KR20200143503A/ko not_active Ceased
- 2013-12-06 AR ARP130104546A patent/AR093844A1/es unknown
- 2013-12-06 TW TW102145031A patent/TWI670062B/zh active
- 2013-12-06 SI SI201331472T patent/SI2928495T1/sl unknown
- 2013-12-06 TW TW107134543A patent/TW201919699A/zh unknown
- 2013-12-06 CN CN201380063714.0A patent/CN105263520B/zh active Active
- 2013-12-06 CA CA2893946A patent/CA2893946A1/en not_active Abandoned
- 2013-12-06 LT LTEP13861470.6T patent/LT2928495T/lt unknown
- 2013-12-06 SG SG10201913783PA patent/SG10201913783PA/en unknown
- 2013-12-06 NZ NZ709215A patent/NZ709215A/en unknown
-
2015
- 2015-06-03 PH PH12015501263A patent/PH12015501263A1/en unknown
- 2015-06-04 IL IL239234A patent/IL239234B/en active IP Right Grant
- 2015-06-05 CL CL2015001558A patent/CL2015001558A1/es unknown
- 2015-06-05 MX MX2019008065A patent/MX2019008065A/es unknown
-
2018
- 2018-08-01 AU AU2018211258A patent/AU2018211258A1/en not_active Abandoned
- 2018-11-20 CL CL2018003292A patent/CL2018003292A1/es unknown
-
2019
- 2019-01-11 JP JP2019003132A patent/JP2019070020A/ja active Pending
- 2019-06-26 CY CY20191100667T patent/CY1122478T1/el unknown
-
2020
- 2020-11-25 LU LU00187C patent/LUC00187I2/fr unknown
- 2020-11-27 CY CY2020040C patent/CY2020040I2/el unknown
- 2020-11-30 LT LTPA2020537C patent/LTC2928495I2/lt unknown
- 2020-11-30 HU HUS2000051C patent/HUS2000051I1/hu unknown
- 2020-11-30 HU HUS2000050C patent/HUS2000050I1/hu unknown
- 2020-11-30 NL NL301079C patent/NL301079I2/nl unknown
-
2021
- 2021-04-21 IL IL282542A patent/IL282542A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016506388A5 (OSRAM) | ||
| JP2016514148A5 (OSRAM) | ||
| RU2015127089A (ru) | Композиции, содержащие антитела к cd38 и леналидомид | |
| JP2016536314A5 (OSRAM) | ||
| JP2014076062A5 (OSRAM) | ||
| JP2017048208A5 (OSRAM) | ||
| RU2015143462A (ru) | Композиции, включающие антитела к cd38 и карфилзомиб | |
| JP2013537418A5 (OSRAM) | ||
| FI3932951T3 (fi) | Menetelmiä ihosyövän hoitamiseksi antamalla PD-1-inhibiittoria | |
| JP2018534933A5 (OSRAM) | ||
| JP2014533279A5 (OSRAM) | ||
| RU2018105846A (ru) | Комбинация антагониста pd-1 с ингибитором egfr | |
| HRP20201656T1 (hr) | Neutralizacija inhibitornih putova u limfocitima | |
| JP2010500370A5 (OSRAM) | ||
| JP2019531764A5 (OSRAM) | ||
| RU2015110981A (ru) | Комбинации и их применение | |
| JP2015532292A5 (OSRAM) | ||
| JP2020503891A5 (OSRAM) | ||
| JP2017507954A5 (OSRAM) | ||
| JP2010500371A5 (OSRAM) | ||
| JP2017515815A5 (OSRAM) | ||
| JP2012523417A5 (OSRAM) | ||
| JP2012136541A5 (OSRAM) | ||
| JP2017503820A5 (OSRAM) | ||
| JP2018520101A5 (OSRAM) |